Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR153191 add-on to methotrexate in active rheumatoid arthritis with inadequate methotrexate response
NL-OMON34750Phase 3Withdrawn
- Sponsor
- Sanofi
- Start
- May 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing SAR153191 + methotrexate with Placebo + methotrexate (2 arms). Planned start May 2010; status: withdrawn.
02
Drugs
sarilumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON34750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34750.